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Table S1.  Association results for sequence variants in TREM2 that are likely to 
affect protein function.   





rs79011726 0.59 1.21 (0.60-2.46) T C 0.17 E151K 
chr6:41236977 0.42 0.78 (0.43-1.42) C A 0.37 splicing 
rs142232675 0.28 1.56 (0.70-3.51) T C 0.12 D87N 
rs143332484 0.48 1.13 (0.80-1.59) T C 0.78 R62H 
rs75932628 3.42x10
-10
 2.92 (2.09-4.09) T C 0.46 R47H 
chr6:41237236 0.78 0.81 (0.18-3.62) T C 0.05 G45E 
       
 
Association with Alzheimer‘s disease in Iceland is shown, using population controls 
age 85 or greater.  Variants are indicated by their rs-names, with the exception of two 
novel variants, which are indicated by their chromosomal location (NCBI Build 36).  
In each case, odds ratios are reported for the minor allele.  Minor allelic frequencies 







Table S2.  Association results for rs75932628-T based on imputation. 
 
cohort Ncase/Ncont P-value OR (95% CI) frequency (%) 
NIA-LOAD 1,026/851 0.095 1.93 (0.89-4.18) 0.70 
eMERGE 566/1,851 0.0026 4.29 (1.66-11.06) 0.34 
Combined 1,592/2,702 0.0014 2.66 (1.46-4.84) - 
 
Shown is the frequency of rs75932628-T in controls.  
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Table S3.  Effect of ApoE ε4 on the association of rs75932628-T with Alzheimer‘s 
disease in Iceland.   
Patient group N freq (%) OR (95% CI) P-value 
AD all  2,773 1.42 3.10 (2.18-4.43) 3.93x10
-10
 
ApoE ε4+  1,511 1.09 2.38 (1.45-3.89) 0.00056 
ApoE ε4-  1,262 1.81 4.03 (2.63-6.16) 1.28x10
-10
 
ApoE ε4+ vs ApoE ε4- N/A N/A 0.60 (0.37-0.98) 0.040 
 
Frequency of risk allele and association results are shown using population controls 




Table S4.  ApoE ε4 analysis in replication cohorts.   
cohort Nε4+ Nε4- frequency (%) ORe4+ vs e4- (95% CI) P-value 
Emory 233 147 0.39 1.26 (0.10-36.74) 1 
Munich 309 205 0.58 3.34 (0.46-77.77) 0.41 
NIA-LOAD 754 271 1.17 2.42 (0.77-7.59) 0.13 
eMERGE 187 310 0.90 0.70 (0.12-3.96) 0.69 
Norway 364 323 0.36 inf (0.89-inf) 0.064 
Combined 1,847 1,256 - 1.79 0.2 
 
Frequency of risk allele in affected individuals with ApoE ε4 information and the OR 
comparing ε4+ vs ε4- AD patients are shown.  The OR value is infinity for the 
Norwegian cohort due to the fact that there are no carriers of the rs75932628-T allele 
in the ε4- group.  Results for the eMERGE data set are based on imputation of ApoE 
ε4. 
 
